Atlanta, GA (PRWEB) January 16, 2012

MissionIR would like to highlight FluoroPharma Medical, Inc. (OTCBB: FPMI). FluoroPharma Medical is a biopharmaceutical business focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to boost patient management by evaluating cardiac illness at the cellular and molecular levels. The organization is currently advancing two products in clinical trials to fulfill crucial unmet medical demands.

In the companys news last week, FluoroPharma Medical announced that its president and CEO, Thijs Spoor, will be presenting at Noble Economic Capital Markets’ Eight Annual Equity Conference.

Mr. Spoor is scheduled to make a presentation to potential corporate partners and investors on Tuesday, January 17th at 11:30 AM ET. The Company’s presentation will be delivered at the Difficult Rock Hotel in Hollywood, Florida.

A reside audio and high-definition video webcast of FluoroPharma Medical’s presentation and a copy of the presentation supplies will be readily available on the Events page of the company’s website http://www.fluoropharma.com. FluoroPharma Medical recommends registering at least ten minutes just before the starting of the presentation to ensure timely access.

About MissionIR

MissionIR is committed to connecting the investment community with organizations that have excellent potential and a strong dedication to creating shareholder value. We know our reputation is based on the integrity of our clients and go to wonderful lengths to make sure the businesses represented adhere to sound enterprise practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR through Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR through Twitter, please visit http://Twitter.com/MissionIR

Please read Complete disclaimer on the MissionIR site: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release might include forward-seeking statements within the which means of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on present expectations and assumptions regarding future events or future performance of the business. Readers are cautioned not to spot undue reliance on these forward-searching statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the organization and its company could lead to the company’s actual outcomes to differ materially from those indicated in any forward-seeking statements.

###